The US FDA decided not to adjust the FY 2019 GDUFA program fee to account for firms that could jump tiers in the middle of the fiscal year, potentially saving ANDA owners some money.
FDA also changed a variable that was used in its calculations, another example of FDA learning how to use its...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?